Contepo is a novel, potentially first-in-class intravenous investigational antibiotic with a broad spectrum of Gram-negative and Gram-positive activity, including activity against most contemporary multi-drug resistant (MDR) strains, such as ESBL-producing Enterobacteriaceae. In January 2019, Nabriva Therapeutics plc announced the acceptance of its new drug application (NDA) by the United States Food and Drug Administration (USFDA).
Download the sample report at: https://www.pharmaproff.com/request-sample/1158
The drug has been granted priority review status by the USFDA for the treatment of complicated urinary tract infections (cUTIs), including acute pyelonephritis. The Prescription Drug User Fee Act (PDUFA) target date for the completion of the FDA’s review of the Contepo NDA is June 30, 2019.
Get the detailed analysis at: https://www.pharmaproff.com/report/contepo
The report will include comprehensive insights about Contepo’s market launch. It will further include clinical trial analysis; strategic development details, such as collaborations, licensing, drug designations, and patent details. This report will also provide comprehensive insights upon how Contepo will evolve in the market as well as within its respective therapeutic class.
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.
Toll-free: +1-888-778-7886 (USA/Canada)
Email: [email protected]